Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell has entered a long-term distribution deal with Talecris Biotherapeutics regarding the drug Prolastin which treats a protein deficiency known as alpha-1-antitrypsin deficiency.
Subscribe to our email newsletter
Alpha-1-antitrypsin deficiency, also known as AATD or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. AATD is also the most common cause of liver disease in children, and emphysema in adults. Individuals suffering from AATD often develop severe obstructive pulmonary diseases (COPD).
Prolastin is indicated for chronic augmentation therapy of individuals having hereditary deficiency of alpha-1 proteinase inhibitor with clinically demonstrable panacinar emphysema.
Under the terms of the agreement, Crucell will serve as the exclusive distributor of Talecris' Prolastin (alpha-1 proteinase inhibitor) in nine Western European countries, replacing current distributor, Bayer.
“Not only does this deal match with our mission to advance in the therapeutic proteins arena but it also strengthens Crucell's global credibility and serves as a major step on our expansion path,” said Crucell's president and CEO, Dr Ronald Brus.
This distribution deal makes the first full use of Crucell's newly integrated pan-European marketing and sales organization created through the acquisitions of Berna Biotech and SBL Vaccines in 2006.